Vitrolife's share capital and number of shares on March 31, 2011

Vitrolife's share capital and number of shares on March 31, 2011

As per March 31, 2011, the total number of shares in Vitrolife AB (publ)
amounts to 19,559,857, of which Vitrolife itself holds 0 shares. The
share capital amounts to SEK 19,951,054.14.

At the beginning of the month the total number of shares in the company
amounted to 19,552,857, of which Vitrolife itself held 0 shares. The
share capital amounted to SEK 19,943,914.14.

The increase in the number of shares by 7,000 during the month of March
is due to the exercising of options to subscribe for new shares under
Vitrolife's outstanding warrants program 2008/2011.

Gothenburg, March 31, 2011
Vitrolife AB (publ)

Queries should be addressed to:
Anne-Lie Sveder, CFO, phone +46 31 721 80 13

________________________________________________________________________
________________

Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for
the preparation, cultivation and storage of human cells, tissue and
organs. The company has business activities within three product areas:
Fertility, Transplantation and Stem Cell Cultivation. The Fertility
product area works with nutrient solutions (media), cryopreservation
products and advanced consumable instruments such as needles and
pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain
organs outside the body in order to select usable organs and keep them
in optimal condition while waiting for transplantation. The Stem Cell
Cultivation product area works with media and instruments to enable the
use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are
sold in more than 85 markets. The company is headquartered in
Gothenburg, Sweden, and there are subsidiaries in USA, Australia,
France, Italy, United Kingdom and Japan. Production facilities are
located in Sweden and the USA. The Vitrolife share is listed on NASDAQ
OMX Stockholm, Small Cap.

________________________________________________________________________
_________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate
identity number 556354-3452.

Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail:
info@vitrolife.com. Website:
www.vitrolife.com (http://www.vitrolife.com/).

Vitrolife is required to publish the information in this press release
in accordance with the Swedish Securities Market Act and the Swedish
Financial Instruments Trading Act. The information was submitted for
publication on Thursday March 31, 2011, at 08:30 a.m. CET.